Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
29.78
-0.24 (-0.80%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.42 - 30.25
52 week 24.95 - 47.97
Open 30.04
Vol / Avg. 663,968.00/677,394.00
Mkt cap 1.70B
P/E     -
Div/yield     -
EPS -1.03
Shares 56.75M
Beta 1.15
Inst. own 111%
Aug 5, 2015
Q2 2015 Insulet Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 14, 2015
Insulet Corp Annual Shareholders Meeting (Estimated)
May 13, 2015
Insulet Corp Annual Shareholders Meeting
Apr 30, 2015
Q1 2015 Insulet Corp Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Insulet Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -19.33% -17.84%
Operating margin -14.10% -12.30%
EBITD margin - -0.03%
Return on average assets -15.62% -17.45%
Return on average equity -57.68% -49.42%
Employees 519 -
CDP Score - -

Address

600 Technology Park Dr Ste 200
BILLERICA, MA 01821-4126
United States - Map
+1-978-6007000 (Phone)
+1-978-6000120 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Company’s principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.

Officers and directors

Michael L. Levitz Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Daniel J. Levangie President - Insulet Drug Delivery
Age: 64
Bio & Compensation  - Reuters
Bradley Thomas CFA Executive Vice President - Human Resources & Organizational Development
Age: 57
Bio & Compensation  - Reuters
Mark Licari Vice President - Global Manufacturing and Operations
Bio & Compensation  - Reuters
David Colleran J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Shacey Petrovic Chief Commercial Officer
Age: 41
Bio & Compensation  - Reuters
Patrick J. Sullivan President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
John A. Fallon Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Charles T. Liamos Director
Age: 55
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters